The Masters haven't mentioned Onyx Pharmaceuticals Inc (NASDAQ:ONXX) in a long time, since our 100%+ gain with our Master Picks Newsletter.  Barron's is jumping on the bandwagon now that shares are down to $33.  Can Nexavar, Onyx's cancer drug take the company and stock back into the spotlight? Onyx Pharmaceuticals Inc's (NASDAQ:ONXX) cancer drug has bright potential in treating several forms of the disease and could raise the biotech company's shares, according to a report on Sunday in Barron's (Paid portion only, thus no link provided). With sales of its drug Nexavar, now approved to treat kidney and liver cancer, expected to hit $1 billion next year, Barron's said one health-care investor is looking for earnings of $1.93 per share, and valuing the stock at $65 to $75 per share....

For those of you that subscribe and read the Quant Method Newsletter - it's time to lock in your 20% gain on Hansen. Not bad for 30 days. The Quant Method has been locking in gains like no one's business. Sign up now and see for yourself.

We will not share our database or processes with the public, but will provide you with the end result, the security to buy or sell and our Quantitative process was built on the following underlying methodology:...